Singapore markets close in 1 hour 17 minutes

NLS Pharmaceutics AG (NLSP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.7700-0.0300 (-3.75%)
At close: 04:00PM EDT
0.7529 -0.02 (-2.22%)
After hours: 05:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 24.97M
Enterprise value 23.97M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)7.91
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.46

Trading information

Stock price history

Beta (5Y monthly) -0.82
52-week change 3-16.75%
S&P500 52-week change 318.47%
52-week high 31.8800
52-week low 30.4200
50-day moving average 30.8932
200-day moving average 31.1875

Share statistics

Avg vol (3-month) 3177.09k
Avg vol (10-day) 352.28k
Shares outstanding 532.43M
Implied shares outstanding 632.43M
Float 814.18M
% held by insiders 138.48%
% held by institutions 119.94%
Shares short (30 Aug 2023) 4119.02k
Short ratio (30 Aug 2023) 41.52
Short % of float (30 Aug 2023) 40.56%
Short % of shares outstanding (30 Aug 2023) 40.37%
Shares short (prior month 30 Jul 2023) 4112.05k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-128.66%
Return on equity (ttm)-862.92%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -15.47M
Net income avi to common (ttm)-16.5M
Diluted EPS (ttm)-0.7900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.95M
Total cash per share (mrq)0.28
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)2.75
Book value per share (mrq)0.10

Cash flow statement

Operating cash flow (ttm)-13.88M
Levered free cash flow (ttm)-8.69M